{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T08:50:48Z","timestamp":1768985448826,"version":"3.49.0"},"reference-count":18,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Cancer"],"published-print":{"date-parts":[[2016,5,1]]},"DOI":"10.1002\/ijc.29972","type":"journal-article","created":{"date-parts":[[2015,12,19]],"date-time":"2015-12-19T15:54:50Z","timestamp":1450540490000},"page":"2293-2299","source":"Crossref","is-referenced-by-count":22,"title":["Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials"],"prefix":"10.1002","volume":"138","author":[{"given":"Michael J.","family":"Sorich","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology; School of Medicine, Flinders University, Adelaide; Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganessan","family":"Kichenadasse","sequence":"additional","affiliation":[{"name":"Flinders Centre for Innovation in Cancer, School of Medicine, Flinders University; Adelaide Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Rowland","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology; School of Medicine, Flinders University, Adelaide; Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Woodman","sequence":"additional","affiliation":[{"name":"Flinders Centre for Epidemiology and Biostatistics, School of Medicine, Flinders University; Adelaide Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arduino A.","family":"Mangoni","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology; School of Medicine, Flinders University, Adelaide; Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,6]]},"reference":[{"key":"10.1002\/ijc.29972-BIB0001|ijc29972-cit-0001","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10552-011-9881-x","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review","volume":"23","author":"Mc Menamin","year":"2012","journal-title":"Cancer Causes Control"},{"key":"10.1002\/ijc.29972-BIB0002|ijc29972-cit-0002","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1002\/ijc.29972-BIB0003|ijc29972-cit-0003","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cncr.28972","article-title":"Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway","volume":"121","author":"Hamnvik","year":"2015","journal-title":"Cancer"},{"key":"10.1002\/ijc.29972-BIB0004|ijc29972-cit-0004","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","article-title":"Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma","volume":"26","author":"Izzedine","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1002\/ijc.29972-BIB0005|ijc29972-cit-0005","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.ejca.2011.04.019","article-title":"Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination","volume":"47","author":"Keizman","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1002\/ijc.29972-BIB0006|ijc29972-cit-0006","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cellsig.2012.02.005","article-title":"Angiotensin II modulates VEGF-driven angiogenesis by opposing effects of type 1 and type 2 receptor stimulation in the microvascular endothelium","volume":"24","author":"Carbajo-Lozoya","year":"2012","journal-title":"Cell Signal"},{"key":"10.1002\/ijc.29972-BIB0007|ijc29972-cit-0007","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1002\/ijc.29972-BIB0008|ijc29972-cit-0008","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","article-title":"A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: final overall survival results and safety update","volume":"49","author":"Sternberg","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1002\/ijc.29972-BIB0009|ijc29972-cit-0009","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1002\/ijc.29972-BIB0010|ijc29972-cit-0010","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1093\/annonc\/mdt288","article-title":"Clinical biomarkers of response in advanced renal cell carcinoma","volume":"24","author":"Ravaud","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1002\/ijc.29972-BIB0011|ijc29972-cit-0011","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1002\/ijc.29972-BIB0012|ijc29972-cit-0012","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"10.1002\/ijc.29972-BIB0013|ijc29972-cit-0013","doi-asserted-by":"crossref","first-page":"F319","DOI":"10.1152\/ajprenal.00139.2011","article-title":"Fetal uninephrectomy in male sheep alters the systemic and renal responses to angiotensin II infusion and AT1R blockade","volume":"301","author":"Singh","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1002\/ijc.29972-BIB0014|ijc29972-cit-0014","first-page":"443","article-title":"Pazopanib","volume":"71","author":"Keisner","year":"2011","journal-title":"Drugs"},{"key":"10.1002\/ijc.29972-BIB0015|ijc29972-cit-0015","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0735-1097(99)00447-7","article-title":"Calcium channel blockers, apoptosis and cancer: is there a biologic relationship?","volume":"34","author":"Mason","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/ijc.29972-BIB0016|ijc29972-cit-0016","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00424-014-1444-z","article-title":"Ttype calcium channels blockers as new tools in cancer therapies","volume":"466","author":"Dziegielewska","year":"2014","journal-title":"Pflugers Arch Eur J Physiol"},{"key":"10.1002\/ijc.29972-BIB0017|ijc29972-cit-0017","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/sim.5686","article-title":"Methods for dealing with time-dependent confounding","volume":"32","author":"Daniel","year":"2013","journal-title":"Stat Med"},{"key":"10.1002\/ijc.29972-BIB0018|ijc29972-cit-0018","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(05)17709-5","article-title":"Subgroup analysis in randomised controlled trials: importance, indications, and interpretation","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.29972","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/ijc.29972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T21:17:26Z","timestamp":1625174246000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.29972"}},"subtitle":["Angiotensin System Inhibitors and Survival"],"short-title":[],"issued":{"date-parts":[[2016,1,6]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,5,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ijc.29972","archive":["Portico"],"relation":{},"ISSN":["0020-7136"],"issn-type":[{"value":"0020-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1,6]]}}}